̽»¨Ö±²¥

Scientists at the ̽»¨Ö±²¥ of Cambridge have shown in animal studies that gene therapy may help repair some of the damage caused in chronic neurodegenerative conditions such as glaucoma and dementia. Their approach demonstrates the potential effectiveness of gene therapy in polygenic conditions – that is, complex conditions with no single genetic cause.

UK researchers are launching a clinical trial to investigate if the drug niclosamide, usually used to treat tapeworms, can prevent COVID-19 infection in vulnerable, high risk kidney patients and reduce the number of people who become seriously ill or die from it.

̽»¨Ö±²¥drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists. Writing in Nature Communications, the researchers describe giving the drug to a patient with COVID-19 and a rare immune disorder, and observing a dramatic improvement in his symptoms and the disappearance of the virus.

Recruitment has begun at three leading Cambridgeshire NHS Trusts for volunteers to take part in the nationwide COVID-19 vaccine trial.

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology.

̽»¨Ö±²¥race is on to find a vaccine against the new COVID-19 coronavirus. Professor Jonathan Heeney explains why a cautious approach is needed and how his team is using new technology developed for influenza and Ebola viruses to target the new infection.

̽»¨Ö±²¥world’s first licensed, downloadable artificial pancreas app for people with type 1 diabetes launches today, based on over a decade of research by Professor Roman Hovorka at the ̽»¨Ö±²¥ of Cambridge and Cambridge ̽»¨Ö±²¥ Hospitals NHS Foundation Trust.

Proteins in our blood could in future help provide a comprehensive ‘liquid health check’, assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine.

Scientists at AstraZeneca, a global biopharmaceutical company, have been working with Cambridge ̽»¨Ö±²¥Â for more than two decades. What are the secrets of their success?

Cambridge scientists are set to benefit from a major cash injection from Cancer Research UK and partners to develop radical new strategies and technologies to detect cancer at its earliest stage.